We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When AbbVie announced its planned $63 billion takeout of Allergan last month, Wall Street blanched. Several analysts questioned whether the two companies were a good fit, blasting AbbVie for doing the deal solely to stave off the loss of revenues when its